Moderna Capitalizes on Stock Jump With $2 Billion Note Offering

Moderna is capitalizing on recent stock gains by issuing $2 billion in convertible notes to fund its cancer vaccine development and reduce existing debt. The offering allows investors to exchange the notes for company shares while providing Moderna with capital for strategic investments. This move reflects the company's confidence in its growth prospects and pivot toward oncology research.